The US Food and Drug Administration (FDA) announced this on Thursday final approval of the first oral pill to be treated COVID-19He paxlovidso far authorized for emergency use.

His statement stated that Paxlovid oral antiviral is fourth drug and first oral antiviral pill approved to treat COVID-19 in adults.

In June, Ecuador will begin deploying a bivalent vaccine against COVID-19

The benefit of Paxlovid has been shown in patients with previous immunity to the virus that causes COVID. The FDA recommends use when the infection is mild to moderate, for adults at high risk of the disease becoming severe..

The risk of hospitalization related to COVID or death from any cause during 28 days of follow-up was 0.2% of 490 people treated with Paxlovid compared to 1.7% of 479 who received placebo.

COVID-19: An additional 31,452 people would have died in Ecuador by 2021, according to the latest figures from the Ministry of Health

“This is evident from today’s approval has met the agency’s strict safety and efficacy standards and that it remains an important treatment option for people at high risk of progression to severe COVID, including those with previous immunity,” the director of the FDA’s Center for Drug Evaluation and Research, Patrizia Cavazzoni, said in the note.